Between Rossari Biotech, Yes Bank FPO, and Bharat Bond ETF, if we take a long-term view and moderate to high-risk profile, we like Rossari the most, given that it ticks the right boxes when it comes to sector and growth profile. At the offer price, Rossari would be valued at a premium relative to some of its larger peers (P/E of around 36) like Vinati, Atul, and Fine Organics. This valuation could be justified given its higher revenue and net income CAGR numbers. … [Read more...] about Rossari Biotech IPO, Bharat Bond ETF & Yes Bank FPO: Where should investors put their money?
Bharat bond etf
"None of the listed chemical companies has the same business as Rossari. We believe Rossari will command a premium over most of its chemical peers as it is net debt-free as well as it has better asset turnover, working capital days, RoE and RoCE better than most of its peers. Only 10 percent of sales are dependent on imported raw material, of which less than 5 percent comes from China. As we are positive on the future outlook for the industry as well as the company, we would recommend subscribing to the issue," Angel Broking said. … [Read more...] about Analysts say subscribe to Rossari Biotech IPO despite high valuation, here is why
"There are a number of reasons why Rossari is a subscribe for short and long term investors alike. Fundamentally it is extremely strong with a topline, EBITDA and net profit CAGR of 32 percent, 63 percent and 67 percent respectively from FY17 to FY20," Nirali Shah, Senior Research Analyst at Samco Securities told Moneycontrol. … [Read more...] about Rossari Biotech IPO opens today, subscribed 34% so far on Day 1